Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database

Current Medical Research and Opinion

Volumn 32, Issue 9, 2016, Pages 1465-1475

  Watson, Louise ^a   Das, Romita ^b   Farquhar, Ruth ^a   Langerman, Haya ^b   Barnett, Anthony H ^c  

^a Explore Epi Ltd   (United Kingdom)

^b MSD   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Diabetes; epidemiology; hyperglycemia; intensification; metformin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; DATA BASE; DEATH; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; ELECTRONIC MEDICAL RECORD; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIGRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; WEIGHT GAIN; AGED; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT; UNITED KINGDOM;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME-TO-TREATMENT; UNITED KINGDOM;

EID: 84961393412     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2016.1157462     Document Type: Article

References (35)

1. WHO Fact Sheet 312. Available at:http://www.who.int/mediacentre/factsheets/fs312/en/ [Last accessed June 2015]
2. Diabetes UK. Diabetes Facts and Stats March 2014. Available at:https://www.diabetes.org.uk. Accessedd June 2015
3. I.M.Stratton, A.I.Adler, H.A.Neil,. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ 2000;321:405-12
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352(UKPDS 33):837-53
5. NICE Clinical Guideline 87. Available at:https://www.nice.org.uk/guidance/cg87 [Last accessed June 2015]
6. M.J.Calvert, R.J.McManus, N.Freemantle. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care:retrospective cohort study. Br J Gen Pract 2007;57:455-60
7. A.N.Goudswaard, R.P.Stolk, P.Zuithoff, Rutten GEHM. Patient characteristics do not predict poor glycaemic control in type 2 diabetes patients treated in primary care. Eur J Epidemiol 2004;19:541-5
8. N.Rodondi, T.Peng, A.J.Karter,. Therapy modifications in response to poorly controlled hypertension, dyslipidemia and diabetes mellitus. Ann Intern Med 2008;144:475-84
9. J.E.Lafata, E.A.Dobie, G.W.Divine,. Sustained hyperglycemia among patients with diabetes:What matters when action is needed? Diabetes Care. 2009;32:1447-52
10. A.Fu, Y.Qiu, M.Davies,. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab 2011;13:765-9
11. F.Á.Guisasola, P.Mavros, G.Nocea,. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries:findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008;10(Suppl 1):8-15
12. A.A.Riedel, H.Heien, J.Wogen, C.A.Plauschinat. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102-10
13. Health & Social Care Information Centre (HSSIC). Healthcare Quality Improvement (HQIP) Report. National Diabetes Audit 2012–2013. Report 1 – Care Processes and Treatment Targets.
14. K.Khunti, M.L.Wolden, B.L.Thorsted,. Clinical inertia in people with type 2 diabetes:a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411-17
15. S.K.Paul, B.L.Thorsted, M.L.Wolden,. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology 2015;14:100
16. C.J.Bailey. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharm Therapeut 2015;98:170-84
17. S.S.Jick, J.A.Kaye, C.Vasilakis-Scaramozza,. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9
18. NHS Reference Costs. Available at:https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 [Last accessed June 2015]
19. Personal Social Services Research Unit (PSSRU). Unit costs of health and social care. Available at:http://www.pssru.ac.uk/project-information [Last accessed June 2015]
20. C.Millett, J.Gray, S.Saxena,. Ethnic disparities in diabetes management and pay-for-performance in the UK:the Wandsworth Prospective Diabetes Study. PLoS Med 2007;4:e191
21. I.Leal, S.A.Romio, M.Schuemie,. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade:a focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol 2013;75:861-8
22. B.Ahrén. Avoiding hypoglycemia:a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63
23. W.M.Wami, F.Buntinx, S.Bartholomeeusen,. Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice. Br J Gen Pract 2013;63:e267-73
24. J.Morgan Classification and Regression Tree Analysis. Report No1. Boston University School of Public Health, 2014
25. G.Lewis, A.Maxwell. Risk factor control is key in diabetic nephropathy. Practitioner 2014;258:13-72
26. S.Cetin, M.Oztürk, N.Barındık,. Increased coronary intervention rate among diabetic patients with poor glycaemic control:a cross-sectional study. Bosn J Basic Med Sci 2014;14:16-20
27. B.Shah, J.Hux, A.Laupacis,. Clinical inertia in response to inadequate glycemic control:do specialists differ from primary care physicians? Diabetes Care 2005;28:600-60
28. M.Rosenthal, M.Fajardo, S.Gilmore,. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care 1998;21:231-5
29. S.Goring, N.Hawkins, G.Wygant,. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy:a systematic review and network meta-analysis. Diabetes Obes Metab 2014;16:433-42
30. U.K.Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes:effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
31. S.Sapkota, J.Brien, J.Greenfield, P.Aslani. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes – impact on adherence. PLoS One 2015;10:e0118296
32. D.B.Lawrence, K.R.Ragucci, L.B.Long,. Relationship of oral antihyperglycemic (sulphonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006;12:466-71
33. A.Ramirez, S.Wolfsgruber, C.Lange,. Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. J Alzheimers Dis 2015;44:1203-12
34. T.Seuring, O.Archangelidi, M.Suhrcke. The economic costs of type 2 diabetes:a global systematic review. PharmacoEconomics 2015;33:811-31
35. C.Ng, J.Lee, M.Toh, Y.Ko. Cost-of-illness studies of diabetes mellitus:a systematic review. Diabetes Res Clin Pr 2014;105:151-63